Clinical Trial Update: Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating umbilical cord-derived Wharton's jelly stem cells for the treatment of acute graft-versus-host disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Umbilical cord-derived Wharton's jelly stem cells (Wharton's jelly-derived mesenchymal stem cells)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Acute Graft Versus Host Disease | Phase 1 | Status: COMPLETED